Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents
Frye RE. Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents. CNS Drugs. 2018 Aug;32(8):713-734. doi: 10.1007/s40263-018-0556-y. PMID: 30105528; PMCID: PMC6105175.
Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism
Connery K, Tippett M, Delhey LM, Rose S, Slattery JC, Kahler SG, Hahn J, Kruger U, Cunningham MW, Shimasaki C, Frye RE. Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Transl Psychiatry. 2018 Aug 10;8(1):148. doi: 10.1038/s41398-018-0214-7. PMID: 30097568; PMCID: PMC6086890.
Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
Rose S, Niyazov DM, Rossignol DA, Goldenthal M, Kahler SG, Frye RE. Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder. Mol Diagn Ther. 2018 Oct;22(5):571-593. doi: 10.1007/s40291-018-0352-x. PMID: 30039193; PMCID: PMC6132446.
A Subset of Patients With Autism Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses
Barone R, Alaimo S, Messina M, Pulvirenti A, Bastin J; MIMIC-Autism Group; Ferro A, Frye RE, Rizzo R. A Subset of Patients With Autism Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses. Front Psychiatry. 2018 Dec 7;9:636. doi: 10.3389/fpsyt.2018.00636. PMID: 30581393; PMCID: PMC6292950.
Variations in Mitochondrial Respiration Differ in IL-1ß/IL-10 Ratio Based Subgroups in Autism Spectrum Disorders
Jyonouchi H, Geng L, Rose S, Bennuri SC, Frye RE. Variations in Mitochondrial Respiration Differ in IL-1ß/IL-10 Ratio Based Subgroups in Autism Spectrum Disorders. Front Psychiatry. 2019 Feb 20;10:71. doi: 10.3389/fpsyt.2019.00071. PMID: 30842746; PMCID: PMC6391925.
Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey
Coleman DM, Adams JB, Anderson AL, Frye RE. Rating of the Effectiveness of 26 Psychiatric and Seizure Medications for Autism Spectrum Disorder: Results of a National Survey. J Child Adolesc Psychopharmacol. 2019 Mar;29(2):107-123. doi: 10.1089/cap.2018.0121. Epub 2019 Feb 6. PMID: 30724573; PMCID: PMC6442266.
Reliability of the Cunningham Panel
Frye RE, Shimasaki C. Reliability of the Cunningham Panel. Translational Psychiatry. 2019 Apr;9(1):129. DOI: 10.1038/s41398-019-0462-1. PMID: 30962420; PMCID: PMC6453973.
Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder
Barone R, Rizzo R, Tabbì G, Malaguarnera M, Frye RE, Bastin J. Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder. Int J Mol Sci. 2019 Apr 16;20(8):1878. doi: 10.3390/ijms20081878. PMID: 30995737; PMCID: PMC6515064.
TACA provides education, support, and hope to families living with autism. Thank you for your support.
Today’s complex disorders (Autism, Lyme, PANS, COVID etc) require a new understanding of the role inflammation, toxins, mitochondrial dysfunction etc are playing. Today’s patients need physicians to obtain new strategies, new diagnostic tools, & new perspectives. MAPS delivers these from leading clinicians & researchers. MAPS takes today’s complex health issues & provides a comprehensive path for clinicians to follow for successful outcomes. MAPS teaches tomorrow’s medicine today. Be part of the future – attend MAPS!
